Arcellx, Inc.
ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic coā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$114.77
Price+0.18%
$0.20
1Y
Price
Market Cap
$6.712b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1948.3%
EBITDA Margin-3513.4%
Net Profit Margin-3563.4%
Free Cash Flow Margin-1948.3%
EBITDA Margin-3513.4%
Net Profit Margin-3563.4%
Free Cash Flow MarginRevenue
$22.286m
-79.3%
1y CAGR-27.2%
3y CAGR-20.4%
5y CAGREarnings
-$228.934m
-113.3%
1y CAGR-34.2%
3y CAGR-73.2%
5y CAGREPS
-$4.07
-103.0%
1y CAGR-24.5%
3y CAGR-48.5%
5y CAGRBook Value
$402.351m
$603.990m
Assets$201.639m
Liabilities$96.258m
DebtDebt to Assets
15.9%
-0.5x
Debt to EBITDAFree Cash Flow
-$212.585m
-119.4%
1y CAGR+3.9%
3y CAGR-14.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company